Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback